Trial Profile
A Phase II Trial of Neoadjuvant IXO Regimen (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) Followed by Combined Modality Capecitabine and Radiation for Locally Resectable Advanced Rectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 18 Nov 2010 New trial record